Key result
Cardiac myeloid sarcoma lacks standardized diagnostic and treatment guidelines due to extreme rarity.
Why the study?
Cardiac Myeloid Sarcoma is a very rare cardiac tumor with limited knowledge and no established guidelines for diagnosis and management.
This review summarizes the clinical features, diagnosis, and management of the rare entity Cardiac Myeloid Sarcoma, for which exact guidelines are currently missing.
Raises awareness for CMS in myeloid malignancy patients with cardiac symptoms; leaves open standardized diagnostic and therapeutic approaches due to extreme rarity.
Granulocytic Sarcomas (GS) also called as Myeloid Sarcomas (MS) or chloromas are the representatives of extramedullary infiltrates of immature myeloid cells including myeloblasts, promyelocytes and myelocytes. Primary cardiac malignancies per se are rare and infiltration of cardiac muscles by secondary malignant cells is also an uncommon finding. Out of these cardiac tumors, contribution of Cardiac Myeloid Sarcoma (CMS) is even more smaller thereby limiting our knowledge about this rare entity. Because of its very lower incidence, an exact guideline for diagnosis and management is still missing and usually haematologists around the world are treating CMS based on their clinical acumen. Aim of this review is to briefly discuss the presenting clinical feature, differential diagnosis, diagnostic workup and management based on published articles related to CMS till date.
No takes yet. Share an insight, caveat, or question.
Archana S. Gautam (2017) conducted a review in Cardiac Myeloid Sarcoma. Cardiac myeloid sarcoma is a rare extramedullary infiltration of immature myeloid cells that currently lacks exact guidelines for diagnosis and management due to its very low incidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: